# A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

> **NCT04354727** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Ascentage Pharma Group Inc.**

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** APG-1252
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04354727
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-15
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354727, "A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04354727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*